Abstract
Objective: To compare a RDI-based in-house ELISPOT-interferon-γ (IFN-γ) assay with a commercial (T-SPOT.TB™) assay for the diagnosis of Mycobocterium tuberculosis (TB) infection and the efficacy of the tuberculin skin test (TST) and ELISPOT assay in detecting latent TB infection (LTBI). Design: Eighty-six subjects (65 household contacts of contagious TB-infected patients, 13 subjects with active or previous TB infection, and 8 with suspected TB infection) were consecutively recruited in the context of a surveillance program. Methods: Enrolled subjects underwent the Mantoux TST and two different ELISPOT-IFN-γ assays: an in-house assay using a pool of selected M. tuberculosis peptides (MTP) and the commercial T-SPOT.TB assay. Results: The in-house and commercial ELISPOT-IFN-γ assays showed almost complete concordance (99%) in diagnosing acute or LTBI. When comparing the efficacy of the TST with the in-house ELISPOT assay in detecting TB infection, a small agreement was observed (k=0.344, P0.0001): 36% of the subjects with a positive TST were ELISPOT-MTP negative and 12% with a negative TST were ELISPOT-MTP positive. Furthermore, 78% of the ELISPOT-MTP negative individuals were ELISPOT- Bacillus Calmette-Guérin (BCG) positive, most of whom had received BCG vaccination. Conclusion: Our in-house ELISPOT assay based on a restricted pool of highly selected peptides is equivalent to the commercial T-SPOT.TB assay, is cheaper and is probably not confounded, unlike the TST, by BCG vaccination in our setting.
| Original language | English |
|---|---|
| Pages (from-to) | 266-272 |
| Number of pages | 7 |
| Journal | Clinical Medicine and Research |
| Volume | 4 |
| Issue number | 4 |
| Publication status | Published - Dec 2006 |
Fingerprint
Keywords
- Bacillus Calmette-Guérin
- CFP-10
- ELISPOT
- ESAT-6
- Household contacts
- IFN-g
- PPD
- Tuberculin skin test
- Tuberculosis
ASJC Scopus subject areas
- Medicine(all)
- Community and Home Care
Cite this
Comparison of an in-house and a commercial RDI-based ELISPOT-IFN-γ assay for the diagnosis of Mycobacterium tuberculosis infection. / Mantegani, Paolo; Piana, Federica; Codecasa, Luigi; Galli, Laura; Scarpellini, Paolo; Lazzarin, Adriano; Cirillo, Daniela; Fortis, Claudio.
In: Clinical Medicine and Research, Vol. 4, No. 4, 12.2006, p. 266-272.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of an in-house and a commercial RDI-based ELISPOT-IFN-γ assay for the diagnosis of Mycobacterium tuberculosis infection
AU - Mantegani, Paolo
AU - Piana, Federica
AU - Codecasa, Luigi
AU - Galli, Laura
AU - Scarpellini, Paolo
AU - Lazzarin, Adriano
AU - Cirillo, Daniela
AU - Fortis, Claudio
PY - 2006/12
Y1 - 2006/12
N2 - Objective: To compare a RDI-based in-house ELISPOT-interferon-γ (IFN-γ) assay with a commercial (T-SPOT.TB™) assay for the diagnosis of Mycobocterium tuberculosis (TB) infection and the efficacy of the tuberculin skin test (TST) and ELISPOT assay in detecting latent TB infection (LTBI). Design: Eighty-six subjects (65 household contacts of contagious TB-infected patients, 13 subjects with active or previous TB infection, and 8 with suspected TB infection) were consecutively recruited in the context of a surveillance program. Methods: Enrolled subjects underwent the Mantoux TST and two different ELISPOT-IFN-γ assays: an in-house assay using a pool of selected M. tuberculosis peptides (MTP) and the commercial T-SPOT.TB assay. Results: The in-house and commercial ELISPOT-IFN-γ assays showed almost complete concordance (99%) in diagnosing acute or LTBI. When comparing the efficacy of the TST with the in-house ELISPOT assay in detecting TB infection, a small agreement was observed (k=0.344, P0.0001): 36% of the subjects with a positive TST were ELISPOT-MTP negative and 12% with a negative TST were ELISPOT-MTP positive. Furthermore, 78% of the ELISPOT-MTP negative individuals were ELISPOT- Bacillus Calmette-Guérin (BCG) positive, most of whom had received BCG vaccination. Conclusion: Our in-house ELISPOT assay based on a restricted pool of highly selected peptides is equivalent to the commercial T-SPOT.TB assay, is cheaper and is probably not confounded, unlike the TST, by BCG vaccination in our setting.
AB - Objective: To compare a RDI-based in-house ELISPOT-interferon-γ (IFN-γ) assay with a commercial (T-SPOT.TB™) assay for the diagnosis of Mycobocterium tuberculosis (TB) infection and the efficacy of the tuberculin skin test (TST) and ELISPOT assay in detecting latent TB infection (LTBI). Design: Eighty-six subjects (65 household contacts of contagious TB-infected patients, 13 subjects with active or previous TB infection, and 8 with suspected TB infection) were consecutively recruited in the context of a surveillance program. Methods: Enrolled subjects underwent the Mantoux TST and two different ELISPOT-IFN-γ assays: an in-house assay using a pool of selected M. tuberculosis peptides (MTP) and the commercial T-SPOT.TB assay. Results: The in-house and commercial ELISPOT-IFN-γ assays showed almost complete concordance (99%) in diagnosing acute or LTBI. When comparing the efficacy of the TST with the in-house ELISPOT assay in detecting TB infection, a small agreement was observed (k=0.344, P0.0001): 36% of the subjects with a positive TST were ELISPOT-MTP negative and 12% with a negative TST were ELISPOT-MTP positive. Furthermore, 78% of the ELISPOT-MTP negative individuals were ELISPOT- Bacillus Calmette-Guérin (BCG) positive, most of whom had received BCG vaccination. Conclusion: Our in-house ELISPOT assay based on a restricted pool of highly selected peptides is equivalent to the commercial T-SPOT.TB assay, is cheaper and is probably not confounded, unlike the TST, by BCG vaccination in our setting.
KW - Bacillus Calmette-Guérin
KW - CFP-10
KW - ELISPOT
KW - ESAT-6
KW - Household contacts
KW - IFN-g
KW - PPD
KW - Tuberculin skin test
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=33846496757&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846496757&partnerID=8YFLogxK
M3 - Article
VL - 4
SP - 266
EP - 272
JO - Clinical Medicine and Research
JF - Clinical Medicine and Research
SN - 1539-4182
IS - 4
ER -